Swissmedic fosters close relationships with foreign authorities and endeavours to develop co-operation in the form of treaties. At the foreground here is the exchange of information within the entire process of authorising medicinal products, market monitoring, and the process of elaborating new regulatory provisions related to therapeutic products.
Article 64 of the Therapeutic Products Act (TPA) regulates the conditions and requirements for the provision of information by Swissmedic within the framework of international mutual administrative assistance and in general for providing information to foreign authorities. Based on this provision, Swissmedic is also authorised to request information from foreign authorities or international organisations. When exchanging data, the national provisions regarding data protection always take precedence for Swissmedic. Based on Article 82a TPA, Swissmedic has concluded information agreements with the authorities shown in the list below.
These international agreements can take the form of legally binding agreements (state treaties) or of declarations of intent that are not legally binding. The agreements or declarations of intent have various titles. They can be called, for example, a Memorandum of Understanding (MoU), a Joint Declaration of Intent (JDI), or a Confidentiality Agreement, Arrangement or Commitment.
Country |
Medicinal products authority | When | Type and scope of agreement | Download |
---|---|---|---|---|
USA | FDA | 2003 | Confidentiality Commitment Therapeutic products |
pdf (PDF, 209 kB, 17.09.2003) |
Australia | TGA | 2015* | MoU Therapeutic products |
pdf (PDF, 2 MB, 22.07.2015) |
Chinese Taipei | TFDA | 2007 | Exchange of Letters (EOL) Medical devices |
pdf (PDF, 473 kB, 04.07.2007) |
Singapore | HSA | 2008 | MoU Therapeutic products |
pdf (PDF, 136 kB, 12.05.2008) |
New Zealand | Medsafe | 2009 | MoU Therapeutic products |
pdf (PDF, 153 kB, 18.05.2009) |
Japan | MHLW / PMDA | 2010 | Confidentiality Arrangement Therapeutic products |
pdf (PDF, 88 kB, 01.01.2010) |
Ireland | HPRA | 2011 | MoU Therapeutic products |
pdf (PDF, 135 kB, 01.02.2011) |
Germany | PEI | 2012 | MoU Biological medicinal products |
pdf (PDF, 151 kB, 24.04.2014) |
Brazil | ANVISA | 2012 | MoU Therapeutic products |
pdf (PDF, 417 kB, 01.01.2012) |
Germany | BfArM | 2014 | Joint Declaration of Intent (JDI) Therapeutic products (biological medicinal products within the PEI mandate) |
pdf (PDF, 77 kB, 07.01.2014) |
South Korea |
MFDS | 2014 | MoU Therapeutic products |
pdf (PDF, 72 kB, 20.01.2014) |
Israel | Ministry of Health | 2014 | JDI Medicinal products |
pdf (PDF, 112 kB, 19.05.2014) |
Republic of South Africa | MCC | 2014 | MoU Therapeutic products |
pdf (PDF, 90 kB, 12.11.2014) |
China |
NMPA | 2015 | Agreement on Cooperation in the Areas of Foodstuffs, Medicinal Products, Medical Devices and Cosmetics | pdf (PDF, 169 kB, 21.01.2015) |
European Union | EMA | 2015 | EOL Medicinal products |
pdf (PDF, 489 kB, 09.07.2015) |
United Kingdom | MHRA | 2016 | MoU Therapeutic products |
pdf (PDF, 90 kB, 10.10.2016) |
Mexico | COFEPRIS | 2016 | MoU Therapeutic products |
pdf (PDF, 23 kB, 04.11.2016) |
Austria | AGES | 2017 | MoU Therapeutic products |
pdf (PDF, 90 kB, 13.03.2017) |
Netherlands | MEB | 2018 | MoU Therapeutic products |
pdf (PDF, 94 kB, 10.09.2018) |
Canada | Health Canada | 2021 | Confidentiality Arrangement | pdf (PDF, 371 kB, 16.04.2021) |
Germany | BVL | 2021 | Memorandum of Understanding | pdf (PDF, 294 kB, 18.05.2021) |
The United Kingdom | Veterinary Medicines Directorate | 2023 | MoU Veterinary medicines |
pdf (PDF, 360 kB, 26.01.2023) |
* updated Version